(Alliance News) - The Covid-19 vaccine from Oxford University and AstraZeneca PLC works well as a third booster shot, according to a study, the Financial Times reported on Wednesday, citing people familiar with the matter.
A third dose was shown to boost the study participants' antibodies to the coronavirus, the newspaper said, despite concern that the immune system might fight off the adenovirus used as a delivery mechanism. Some scientists have feared that repeated use of the adenovirus vector - an inactivated cold virus - could stop the immune system recognising the virus's spike protein.
However, the study found the participants' immune systems reacted to the adenovirus used to deliver the protein, but it had a far more significant reaction to the protein, according to the FT.
Citing another person familiar with the trial, the FT said results were described as "unbelievable" and strong enough to "blow through almost any variant".
https://www.ft.com/content/c5297d58-ad6d-490f-89e0-74f9c13377e4
AstraZeneca shares were marginally higher at 7,931.00 pence in London early Wednesday.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)
